CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, a neuromodulation device that enhance symptoms for patients with heart failure by delivering electrical pulses to baroreceptors. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

CVRx, Inc.

Cvrx, Inc. ($CVRX) announced an update on their ongoing clinical study. The BAROSTIM THERAPY™ in Resistant Hypertension registry, officially titled...

CVRx’s BAROSTIM Registry: Real‑World Hypertension Data That Could Move the Stock

Cvrx, Inc. ($CVRX) announced an update on their ongoing clinical study. The study called “BAROSTIM THERAPY in Heart Failure With Reduced Ejection F...

CVRX’s Barostim Heart Failure Registry: Real‑World Data That Matters for Investors

Cvrx, Inc. ($CVRX) announced an update on their ongoing clinical study. The BAROSTIM NEO Hypertension Pivotal Trial extension is designed to track ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CVRX	$3.00	-0.66%	301.00K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CVRX	$3.00	-0.7%	301.00K
3
4
5
6

CVRX

Get CVRx, Inc. Data in Excel

Get CVRx, Inc. Data in Excel